Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer

Brendan D. Curti, Augusto C. Ochoa, Gerry C. Powers, William C. Kopp, W. Gregory Alvord, John Edward Janik, Barry L. Gause, Barbara Dunn, Michael S. Kopreski, Robert Fenton, Arnold Zea, Claudio Dansky-Ullmann, Susan Strobl, Linda Harvey, Edward Nelson, Mario Sznol, Dan L. Longo

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Purpose: We performed a phase I trial to determine whether in viva expansion of activated CD4+ T cells was possible in cancer patients. 111Indium labeling was used to observe trafficking patterns of the infused stimulated CD4+ T cells. The influence of cyclophosphamide (CTX) dosing on immunologic outcome was also examined. Patients and Methods: Patients with advanced solid tumors or non-Hodgkin's lymphoma received CTX at 300 or 1,000 mg/m2 intravenously (IV). Leukapheresis was performed to harvest peripheral- blood mononuclear cells (PBMCs) either just before the CTX dose, or when the patient was either entering or recovering from the leukocyte nadir induced by CTX. An enriched population of CD4+ T cells was obtained by negative selection. The CD4+ T cells were activated ex vivo with anti-CD3, cultured with interleukin-2 (IL-2) for 4 days, and adoptively transferred. After adoptive transfer, patients received IL-2 (9.0 x 106 IU/m2/d) by continuous infusion for 7 days. Results: The absolute number of CD4+, CD4+/DR+, and CD4+/CD45RO+ T cells increased in a statistically significant fashion in all cohorts after the first course of therapy. The degree of CD4 expansion was much greater than CD8 expansion, which resulted in a CD4:CD8 ratio that increased in 26 of 31 patients. The greatest in vivo CD4 expansion occurred when cells were harvested as patients entered the CTX-induced nadir. One complete response (CR), two partial responses (PRs), and eight minor responses were observed. Trafficking of 111Indium-labeled CD4 cells to subcutaneous melanoma deposits was also documented. Conclusion: CD4+ T cells can be expanded in vivo in cancer patients, which results in increased CD4:CD8 ratios. The timing of pheresis in relation to CTX administration influences the degree of CD4 expansion. Tumor responses with this regimen were observed in a variety of tumors, including melanoma and non-Hodgkin's lymphoma; a high percentage of patients had at least some tumor regression from the regimen that produced the greatest CD4+ T-cell expansion.

Original languageEnglish (US)
Pages (from-to)2752-2760
Number of pages9
JournalJournal of Clinical Oncology
Volume16
Issue number8
DOIs
StatePublished - Jan 1 1998

Fingerprint

Cyclophosphamide
Interleukin-2
T-Lymphocytes
Neoplasms
CD4-CD8 Ratio
Non-Hodgkin's Lymphoma
Melanoma
Leukapheresis
Blood Component Removal
Adoptive Transfer
Interleukin-4
Blood Cells
Leukocytes
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. / Curti, Brendan D.; Ochoa, Augusto C.; Powers, Gerry C.; Kopp, William C.; Alvord, W. Gregory; Janik, John Edward; Gause, Barry L.; Dunn, Barbara; Kopreski, Michael S.; Fenton, Robert; Zea, Arnold; Dansky-Ullmann, Claudio; Strobl, Susan; Harvey, Linda; Nelson, Edward; Sznol, Mario; Longo, Dan L.

In: Journal of Clinical Oncology, Vol. 16, No. 8, 01.01.1998, p. 2752-2760.

Research output: Contribution to journalArticle

Curti, BD, Ochoa, AC, Powers, GC, Kopp, WC, Alvord, WG, Janik, JE, Gause, BL, Dunn, B, Kopreski, MS, Fenton, R, Zea, A, Dansky-Ullmann, C, Strobl, S, Harvey, L, Nelson, E, Sznol, M & Longo, DL 1998, 'Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer', Journal of Clinical Oncology, vol. 16, no. 8, pp. 2752-2760. https://doi.org/10.1200/JCO.1998.16.8.2752
Curti, Brendan D. ; Ochoa, Augusto C. ; Powers, Gerry C. ; Kopp, William C. ; Alvord, W. Gregory ; Janik, John Edward ; Gause, Barry L. ; Dunn, Barbara ; Kopreski, Michael S. ; Fenton, Robert ; Zea, Arnold ; Dansky-Ullmann, Claudio ; Strobl, Susan ; Harvey, Linda ; Nelson, Edward ; Sznol, Mario ; Longo, Dan L. / Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 8. pp. 2752-2760.
@article{0846ae5a3eae4706b1e0deec044e96f3,
title = "Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer",
abstract = "Purpose: We performed a phase I trial to determine whether in viva expansion of activated CD4+ T cells was possible in cancer patients. 111Indium labeling was used to observe trafficking patterns of the infused stimulated CD4+ T cells. The influence of cyclophosphamide (CTX) dosing on immunologic outcome was also examined. Patients and Methods: Patients with advanced solid tumors or non-Hodgkin's lymphoma received CTX at 300 or 1,000 mg/m2 intravenously (IV). Leukapheresis was performed to harvest peripheral- blood mononuclear cells (PBMCs) either just before the CTX dose, or when the patient was either entering or recovering from the leukocyte nadir induced by CTX. An enriched population of CD4+ T cells was obtained by negative selection. The CD4+ T cells were activated ex vivo with anti-CD3, cultured with interleukin-2 (IL-2) for 4 days, and adoptively transferred. After adoptive transfer, patients received IL-2 (9.0 x 106 IU/m2/d) by continuous infusion for 7 days. Results: The absolute number of CD4+, CD4+/DR+, and CD4+/CD45RO+ T cells increased in a statistically significant fashion in all cohorts after the first course of therapy. The degree of CD4 expansion was much greater than CD8 expansion, which resulted in a CD4:CD8 ratio that increased in 26 of 31 patients. The greatest in vivo CD4 expansion occurred when cells were harvested as patients entered the CTX-induced nadir. One complete response (CR), two partial responses (PRs), and eight minor responses were observed. Trafficking of 111Indium-labeled CD4 cells to subcutaneous melanoma deposits was also documented. Conclusion: CD4+ T cells can be expanded in vivo in cancer patients, which results in increased CD4:CD8 ratios. The timing of pheresis in relation to CTX administration influences the degree of CD4 expansion. Tumor responses with this regimen were observed in a variety of tumors, including melanoma and non-Hodgkin's lymphoma; a high percentage of patients had at least some tumor regression from the regimen that produced the greatest CD4+ T-cell expansion.",
author = "Curti, {Brendan D.} and Ochoa, {Augusto C.} and Powers, {Gerry C.} and Kopp, {William C.} and Alvord, {W. Gregory} and Janik, {John Edward} and Gause, {Barry L.} and Barbara Dunn and Kopreski, {Michael S.} and Robert Fenton and Arnold Zea and Claudio Dansky-Ullmann and Susan Strobl and Linda Harvey and Edward Nelson and Mario Sznol and Longo, {Dan L.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1200/JCO.1998.16.8.2752",
language = "English (US)",
volume = "16",
pages = "2752--2760",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer

AU - Curti, Brendan D.

AU - Ochoa, Augusto C.

AU - Powers, Gerry C.

AU - Kopp, William C.

AU - Alvord, W. Gregory

AU - Janik, John Edward

AU - Gause, Barry L.

AU - Dunn, Barbara

AU - Kopreski, Michael S.

AU - Fenton, Robert

AU - Zea, Arnold

AU - Dansky-Ullmann, Claudio

AU - Strobl, Susan

AU - Harvey, Linda

AU - Nelson, Edward

AU - Sznol, Mario

AU - Longo, Dan L.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Purpose: We performed a phase I trial to determine whether in viva expansion of activated CD4+ T cells was possible in cancer patients. 111Indium labeling was used to observe trafficking patterns of the infused stimulated CD4+ T cells. The influence of cyclophosphamide (CTX) dosing on immunologic outcome was also examined. Patients and Methods: Patients with advanced solid tumors or non-Hodgkin's lymphoma received CTX at 300 or 1,000 mg/m2 intravenously (IV). Leukapheresis was performed to harvest peripheral- blood mononuclear cells (PBMCs) either just before the CTX dose, or when the patient was either entering or recovering from the leukocyte nadir induced by CTX. An enriched population of CD4+ T cells was obtained by negative selection. The CD4+ T cells were activated ex vivo with anti-CD3, cultured with interleukin-2 (IL-2) for 4 days, and adoptively transferred. After adoptive transfer, patients received IL-2 (9.0 x 106 IU/m2/d) by continuous infusion for 7 days. Results: The absolute number of CD4+, CD4+/DR+, and CD4+/CD45RO+ T cells increased in a statistically significant fashion in all cohorts after the first course of therapy. The degree of CD4 expansion was much greater than CD8 expansion, which resulted in a CD4:CD8 ratio that increased in 26 of 31 patients. The greatest in vivo CD4 expansion occurred when cells were harvested as patients entered the CTX-induced nadir. One complete response (CR), two partial responses (PRs), and eight minor responses were observed. Trafficking of 111Indium-labeled CD4 cells to subcutaneous melanoma deposits was also documented. Conclusion: CD4+ T cells can be expanded in vivo in cancer patients, which results in increased CD4:CD8 ratios. The timing of pheresis in relation to CTX administration influences the degree of CD4 expansion. Tumor responses with this regimen were observed in a variety of tumors, including melanoma and non-Hodgkin's lymphoma; a high percentage of patients had at least some tumor regression from the regimen that produced the greatest CD4+ T-cell expansion.

AB - Purpose: We performed a phase I trial to determine whether in viva expansion of activated CD4+ T cells was possible in cancer patients. 111Indium labeling was used to observe trafficking patterns of the infused stimulated CD4+ T cells. The influence of cyclophosphamide (CTX) dosing on immunologic outcome was also examined. Patients and Methods: Patients with advanced solid tumors or non-Hodgkin's lymphoma received CTX at 300 or 1,000 mg/m2 intravenously (IV). Leukapheresis was performed to harvest peripheral- blood mononuclear cells (PBMCs) either just before the CTX dose, or when the patient was either entering or recovering from the leukocyte nadir induced by CTX. An enriched population of CD4+ T cells was obtained by negative selection. The CD4+ T cells were activated ex vivo with anti-CD3, cultured with interleukin-2 (IL-2) for 4 days, and adoptively transferred. After adoptive transfer, patients received IL-2 (9.0 x 106 IU/m2/d) by continuous infusion for 7 days. Results: The absolute number of CD4+, CD4+/DR+, and CD4+/CD45RO+ T cells increased in a statistically significant fashion in all cohorts after the first course of therapy. The degree of CD4 expansion was much greater than CD8 expansion, which resulted in a CD4:CD8 ratio that increased in 26 of 31 patients. The greatest in vivo CD4 expansion occurred when cells were harvested as patients entered the CTX-induced nadir. One complete response (CR), two partial responses (PRs), and eight minor responses were observed. Trafficking of 111Indium-labeled CD4 cells to subcutaneous melanoma deposits was also documented. Conclusion: CD4+ T cells can be expanded in vivo in cancer patients, which results in increased CD4:CD8 ratios. The timing of pheresis in relation to CTX administration influences the degree of CD4 expansion. Tumor responses with this regimen were observed in a variety of tumors, including melanoma and non-Hodgkin's lymphoma; a high percentage of patients had at least some tumor regression from the regimen that produced the greatest CD4+ T-cell expansion.

UR - http://www.scopus.com/inward/record.url?scp=0031928111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031928111&partnerID=8YFLogxK

U2 - 10.1200/JCO.1998.16.8.2752

DO - 10.1200/JCO.1998.16.8.2752

M3 - Article

VL - 16

SP - 2752

EP - 2760

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -